Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
28/08/2025 16:44
Aug 28 (Reuters) - Biophytis SA ALBPS.PA: BIOPHYTIS SA: RECEIVES EMA AND BELGIAN REGULATORY APPROVAL TO INITIATE PHASE 3 SARCOPENIA CLINICAL TRIAL Source text: [ID:n0001104659-25-084446] Further company coverage: ALBPS.PA ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon